Abstract

Increasing efforts have been done to figure out the association between lncRNAs and complex diseases. Many computational models construct various lncRNA similarity networks, disease similarity networks, along with known lncRNA-disease associations to infer novel associations. However, most of them neglect the structural difference between lncRNAs network and diseases network, hierarchical relationships between diseases and pattern of newly discovered associations. In this study, we developed a model that performs Bi-Random Walks to predict novel LncRNA-Disease Associations (BRWLDA in short). This model utilizes multiple heterogeneous data to construct the lncRNA functional similarity network, and Disease Ontology to construct a disease network. It then constructs a directed bi-relational network based on these two networks and available lncRNAs-disease associations. Next, it applies bi-random walks on the network to predict potential associations. BRWLDA achieves reliable and better performance than other comparing methods not only on experiment verified associations, but also on the simulated experiments with masked associations. Case studies further demonstrate the feasibility of BRWLDA in identifying new lncRNA-disease associations.

Highlights

  • The central dogma of molecular biology assumes genetic information is stored in protein-coding genes

  • To quantitatively study the performance of the proposed method and that of other related comparing methods, two different orientations of leave-one-out cross-validation (LOOCV) are implemented on experimentally verified lncRNAdisease associations collected from GeneRIFs [52] and LncRNADisease [18]

  • Increasing evidences show that long ncRNAs (lncRNAs) play essential roles in various biological processes and they have association with various complex human diseases [7,8,9,10,11,12]

Read more

Summary

Introduction

The central dogma of molecular biology assumes genetic information is stored in protein-coding genes. LncRNA HOTAIR (HOX antisense intergenic RNA) has 100 to approximately 2000-fold expression levels in breast cancer metastases based on quantitative PCR. It controls the pattern of histone modifications and regulates gene expression by binding to histone modifiers, PRC2 and LSD1 complexes [13, 14]. By down-regulating H19, an lncRNA confirmed more than 20 years ago [15], the breast and lung cancer cell clonogenicity and anchorage-independent growth can be significantly decreased [16]. H19 is involved with www.impactjournals.com/oncotarget various diseases and can be used as a potential prognostic biomarker for the early recurrence of bladder cancer [17]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call